Lead Sponsor

Daiichi Sankyo Co., Ltd.

Age

30 - 70 years

Sex

ALL

Healthy Volunteers

No

•clinical diagnosis of diabetic nephropathy in patients with type 2 diabetes
•albumin-to-creatinine ratio \>= 300 mg/g creatinine in first morning urinalysis
•serum creatinine between 1.0 and 2.5 mg/dL in women and between 1.2 and 2.5 mg/dL in men

•type 1 diabetes
•non-diabetic nephropathy
•history of myocardial infarction
•history of cardiac bypass grafting within 3 months
•history of percutaneous coronary intervention (PCI) within 6 months
•history of carotid artery or peripheral artery revascularization within 6 months
•stroke or transient ischemic attack (TIA) within 1 year
•unstable angina pectoris
•heart failure of NYHA functional classes III or IV
•rapid progression of kidney disease within 3 months
•severe orthostatic hypotension
•serum potassium level =\<3.5 mEq(mmol)/L or =\>5.5 mEq(mmol)L
•history of rapid elevation of the serum creatinine level after starting treatment with AII receptor antagonists or ACE inhibitors
•poor glycemic control: HbA1c level =\>11%
•history of myocardial infarction (MI) or coronary artery bypass grafting (CABG) within 3 months

Related studies

NCT07581145 · Foot Ulcer Due to Type 2 Diabetes Mellitus

NCT07023406 · Type 2 Diabetes Mellitus (T2DM)

NCT05692388 · Diabetic Nephropathy Type 2 - Uncontrolled, Diabetes Mellitus, Type 2, and more

NCT06613854 · Type 2 Diabetes Mellitus (T2DM)

NCT06821399 · Diabetes, Diabetic Retinopathy, and more

ORIENT: Olmesartan Reducing Incidence of End Stage Renal Disease in Diabetic Nephropathy Trial